ATE328091T1 - Oligoepitop-peptid des prostata-spezifischen antigens - Google Patents

Oligoepitop-peptid des prostata-spezifischen antigens

Info

Publication number
ATE328091T1
ATE328091T1 AT97916850T AT97916850T ATE328091T1 AT E328091 T1 ATE328091 T1 AT E328091T1 AT 97916850 T AT97916850 T AT 97916850T AT 97916850 T AT97916850 T AT 97916850T AT E328091 T1 ATE328091 T1 AT E328091T1
Authority
AT
Austria
Prior art keywords
psa
specific antigen
prostate specific
peptide
oligoepitope
Prior art date
Application number
AT97916850T
Other languages
English (en)
Inventor
Jeffrey Schlom
Kwong-Yok Tsang
Sam Zaremba
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE328091T1 publication Critical patent/ATE328091T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97916850T 1996-03-20 1997-03-19 Oligoepitop-peptid des prostata-spezifischen antigens ATE328091T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/618,936 US6946133B1 (en) 1996-03-20 1996-03-20 Prostate specific antigen oligo-epitope peptide

Publications (1)

Publication Number Publication Date
ATE328091T1 true ATE328091T1 (de) 2006-06-15

Family

ID=24479748

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97916850T ATE328091T1 (de) 1996-03-20 1997-03-19 Oligoepitop-peptid des prostata-spezifischen antigens

Country Status (7)

Country Link
US (5) US6946133B1 (de)
EP (1) EP0888456B1 (de)
AT (1) ATE328091T1 (de)
AU (1) AU2535997A (de)
DE (1) DE69735995T2 (de)
ES (1) ES2262176T3 (de)
WO (1) WO1997035021A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US6946133B1 (en) * 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
WO1999024596A1 (en) * 1997-11-12 1999-05-20 Valentis, Inc. Expression plasmids for multiepitope nucleic acid-based vaccines
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
AU2001255196A1 (en) * 2000-03-29 2001-10-08 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
CN100400099C (zh) * 2001-01-04 2008-07-09 北京迪威华宇生物技术有限公司 预防和治疗人前列腺癌的重组蛋白疫苗
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
DE60235041D1 (de) 2001-11-30 2010-02-25 Us Gov Health & Human Serv Und ihre verwendung
WO2005062977A2 (en) * 2003-12-23 2005-07-14 The Regents Of The University Of California Prostate cancer specific internalizing human antibodies
AU2005249450A1 (en) 2004-05-27 2005-12-15 Centocor, Inc. Cynomolgus prostate specific antigen
WO2006023598A2 (en) * 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
ES2641892T3 (es) * 2009-08-26 2017-11-14 Selecta Biosciences, Inc. Composiciones que inducen la ayuda de las células T
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
KR101171381B1 (ko) * 2010-05-28 2012-08-13 한국과학기술원 암세포에 특이적인 활성을 갖는 신규 펩타이드 항암제
WO2012019125A2 (en) 2010-08-06 2012-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for prostate cancer and methods for their detection
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
WO2013116656A1 (en) * 2012-02-03 2013-08-08 Emory University Immunostimulatory compositions, particles, and uses related thereto
US9575053B2 (en) 2012-03-30 2017-02-21 Kyoto University Urinary biomarker for use in test for prostate cancer
EA201590783A1 (ru) 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
KR20150130284A (ko) * 2013-03-15 2015-11-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 백신 및 이를 이용한 치료 방법
EP3456700A1 (de) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Markierte inhibitoren des prostataspezifischen membranantigens (psma), deren verwendung als kontrastmittel und pharmazeutika zur behandlung von prostatakrebs
EP3533473A3 (de) 2013-11-14 2019-12-18 Endocyte, Inc. Verbindungen für positronenemissionstomografie
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
TW201708260A (zh) * 2015-07-22 2017-03-01 優瑞卡醫療公司 靶向ｐｓａ胜肽／ｍｈｃ複合體之構築體及其用途
US20190183870A1 (en) 2016-01-05 2019-06-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
WO2020030954A1 (en) * 2018-08-09 2020-02-13 Integrative Medicine Clinic, Sia Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
US20230287067A1 (en) * 2020-01-21 2023-09-14 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Human immunogenic epitopes of hemo and hhla2 human endogenous retroviruses (hervs)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204096A (en) * 1984-03-07 1993-04-20 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
AU648261B2 (en) 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
WO1994003205A1 (en) 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
BR9406652A (pt) 1993-03-05 1996-09-10 Cytel Corp Composição
US5516639A (en) * 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
ES2245778T3 (es) 1993-08-11 2006-01-16 Jenner Technologies Vacuna contra el cancer de prostata.
EP0652014A1 (de) 1993-11-10 1995-05-10 National Institute Of Immunology Behandlung von Prostatahypertrophie
ZA941645B (en) * 1994-03-09 1995-01-13 South To South Co Operation In Antibodies specifically reactive against human prostate specific antigen.
CA2187775A1 (en) * 1994-04-15 1995-10-26 Aaron E. Katz Method for molecular staging of prostate cancer
WO1995028958A1 (en) 1994-04-22 1995-11-02 Sloan-Kettering Institute For Cancer Research Induction of cytotoxic t lymphocytes (ctl) using antigenic peptides and a suitable adjuvant
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US6165460A (en) 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
US6946133B1 (en) * 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide

Also Published As

Publication number Publication date
WO1997035021A3 (en) 1997-10-30
EP0888456A2 (de) 1999-01-07
WO1997035021A2 (en) 1997-09-25
US20070098691A1 (en) 2007-05-03
US7871986B2 (en) 2011-01-18
US20050196806A1 (en) 2005-09-08
EP0888456B1 (de) 2006-05-31
US7547773B2 (en) 2009-06-16
US20110091498A1 (en) 2011-04-21
DE69735995T2 (de) 2007-04-19
US6946133B1 (en) 2005-09-20
ES2262176T3 (es) 2006-11-16
US8178508B2 (en) 2012-05-15
DE69735995D1 (de) 2006-07-06
US20090263425A1 (en) 2009-10-22
AU2535997A (en) 1997-10-10

Similar Documents

Publication Publication Date Title
DE69735995D1 (de) Oligoepitop-peptid des prostata-spezifischen antigens
NO983999L (no) Peptidimmunogener for vaksinasjon mot og behandling av allergi
DK0584266T3 (da) Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf
DE69434475D1 (de) Impfstoff gegen prostatakrebs
ATE418562T1 (de) Ctl epitope des epstein-barr virus
DK0835133T3 (da) Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf
MY119276A (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
AU2953895A (en) Multi-stage cascade boosting vaccine
DE69924826T8 (de) Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
NO991691L (no) Cancer immunoterapi ved Õ bruke tumorceller kombinert med blandede lymfosytter
NO963508L (no) Urease-basert vaksine og behandling av Helicobacter-infeksjon
WO2001058485A3 (en) Prophylactic and therapeutic antibodies against vaccina virus antigens
WO1998058956A3 (en) Methods for inducing an immune response involving prime-boost protocols
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
HUP9801266A2 (hu) Multimer, rekombináns ureázvakcina
AU4396401A (en) Composition and method for the prevention and/or the treatment of allergy
ATE147782T1 (de) Primaten-lentivirus impfstoffe
DE69723580D1 (de) Impfstoff gegen metastasierenden kolorektalkrebs.
EA200200602A1 (ru) Вакцина, содержащая штаммы lactobacillus, для лечения воспаления предстательной железы и доброкачественной гиперплазии предстательной железы
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
ATE255594T1 (de) Hepatitis b inhibitoren
WO2001004318A3 (en) Myxoma virus genes for immune modulation
AU2002336244A1 (en) Trp2 isoform trp2-6b containing hla-a2-restricted epitopes
ES2167180A1 (es) Preparacion de concentrados terapeuticos de factor viii antigenico y aplicacion correspondiente.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties